A hypothesis while we all wait:The Covid trial was a success....

A hypothesis while we all wait:

The Covid trial was a success. The trial duration was very short (relative to the two HIV trials) and no where near as complex. It would have finished at least a month or two ago. If it was a failure and of no interest to BP, BIT would have released these results to the market. They haven't. Meaning, as BMD stated, that the trial results are being treated as confidential, given it is the same BIT225 compound used in the longer and more complex HIV trials. BIT would be negotiating with BP for both outcomes, plus HCV, plus the other compounds in the Biotron cupboard. The HIV results are either ready and BIT is negotiating with BP (one or more) or they are not ready. Either way, given no headline results on the Covid trial, there will be no headline results on the HIV trials (unless they are a failure) - as are commercially confidential.

With rose coloured glasses on, the delay is likely to be protracted as this type of deal will require BP to complete their own internal and third party scientific review, undertake commercial negotiations, draf of legal agreements and seek board approval.

Cannot see how negative results would not be released to the market - but can easily see why successful results would not be, and further why there may be no news for some time.

A flaw in the above is BIT management would have known the above pathway - so why say imminent? Was this a BP requirement perhaps? Maybe BIT were planning to release positive headline data but have been advised or asked not to???

Who knows - but GLTA